There are many, many ELISA tests out there to choose from, and making the best selection can sometimes be a bit daunting. In this post, let’s take a look at the key points to keep in mind.
As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy research. Indeed, promising molecules tested in clinical trials and approved are giving new hope for cancer treatment. Beyond checkpoint receptors, the Enzymatic pathway also regulates the immune system and provides additional targets for Drug Development, and may increase the chances of clinical success in Cancer treatment.
In addition to already developed Immune Checkpoint Reporter cell lines (as introduced in my previous post), BPS Bioscience also provide tools to study the enzymatic pathway, such as the tryptophan catabolism pathway controlled by IDO1: The IDO / TDO pathway. [Read more…]
As discussed previously in our recent Drug Discovery post, Immunotherapy is one of the central research fields for various disease treatments and also certain cancers. A major regulator of immune homoeostasis and preventing autoimmunity, but potentially dysregulated in various cancers, Immune Checkpoint targeting has already led to promising treatment molecules (Nivolumab, Pembrolizumab…).
To face the challenges of Immune system complexity and the tumor microenvironment, BPS Biosciences have developed several reporter cellular lines (the full listing is here) to complement Biochemical assays. By providing more physiological outcomes in a cellular context (functionality of the whole cell signaling pathway) BPS cell lines allow, for example, the identification of an agonist vs antagonistic effect of your candidate. [Read more…]
Gene reporter assays are widely used in research and Drug Discovery. The development of such cell lines is often time-consuming and costly, sometimes upwards of 5-20k € per cell line. And once these cell lines are finally validated, why jeopardize your results with cheap and low-end detection kits? They could impact the reproducibility of your experiments in unintended and unanticipated ways. BPS Bioscience has developed two reliable and extremely powerful luciferase detection kits: the ONE-Step™ Luciferase Assay System (#60690) and the Dual Luciferase Assay System (#60683). [Read more…]
Biomolecule conjugation is critical to many applications such as bead-based assays, ELISA and chromatography by affinity. Unfortunately the classical methods are known to be tedious and with low efficiency. Trilink Biotechnologies has come this year with the solution, an innovative chromophore-linker-based conjugation chemistry called ChromaLink. [Read more…]
Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications
A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA enhance gene editing in primary cells. To demonstrate this, Matthew H Porteus’s team chose the targeted genes CCR5, HBB and IL2RG respectively involved in anti-HIV clinical trials, cell anaemia and thalassemia, and severe combined immunodeficiency. More recently, the same team tested several modified CAS9 mRNA. You can find the practical results on this poster introduced at the ASGC. [Read more…]
PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda® – humanized monoclonal IgG4 antibody against human cell surface receptor PD-1) for use in some patients with advanced gastric stomach cancer (see NIH-NCI news). However, response to these treatments is not guaranteed for each patient. With the complexity of the immune system and tumour microenvironment, providing more physiological outcomes for immunotherapies is necessary. Biochemical assays alone cannot consider the functionality of the whole cell signalling pathway. Complementing them with cell-based assays provides a comprehensive approach for identifying and developing new and improved immunotherapy treatments. Cellular line engineering has simplified and accelerated the development of such immunoassays. Targets have been chosen from both immune activators and suppressors with the aim of obtaining precise control of the immune system.
BPS Bioscience have engineered 6 cellular lines, turning them into cell-based reporter assays for Human Immune Checkpoint research. I’d like to present a summary of how each cellular line functions.
Use of validated antibodies is primordial for Breast Cancer research and related biomarker discovery. Here, we’ll review the main biomarkers involved in this disease and introduce the most popular validated primary antibodies used by our clients.
Generating high-quality Immunoprecipitation & Western Blot (IP & WB) data has never been easier. See how you can easily achieve this in our Tips & Tricks section to get clean WB-IP.
In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of cancer. Based on inducing, enhancing or suppressing an immune response, this therapeutic manipulation has led to promising clinical results.
Major regulators of Immune activation, Immune checkpoints play a key role in maintaining immune homoeostasis and preventing autoimmunity. However in some cancers, these checkpoints can be used to avoid any activation of the immune response against cancer cells. Immunotherapies based on targeting immune checkpoint pathways in Drug Discovery, have already led to the development of promising molecules (Nivolumab, Pembrolizumab…) tested in clinical trials and approved, which are giving new hope for cancer treatments. [Read more…]